Carpal tunnel syndrome was linked to wild-type transthyretin amyloidosis in new research, highlighting the importance of early diagnosis for better heart failure outcomes.
Carpal tunnel syndrome (CTS) was linked with wild-type transthyretin amyloidosis (ATTRwt)—a progressive disease that often manifests as heart failure—in a study published in The Journal of Hand Surgery.1 The findings suggest timely diagnosis and referral to cardiologists may help improve outcomes.
Cardiac amyloidosis (CA) has become an increasingly recognized cause of heart failure in recent years, with prognosis significantly worse once the symptoms of cardiac amyloidosis manifest, the authors explained.
Carpal tunnel syndrome may prove to be a potential indicator for cardiac amyloidosis. | Image Credit: bluebay2014-stock.adobe.com
“Cardiac amyloidosis is a progressive disease that, if left untreated, often manifests as heart failure and becomes life-threatening. Therefore, an early diagnosis is crucial,” the study authors wrote. “However, the definitive diagnosis of cardiac amyloidosis is extremely challenging, with a high misdiagnosis rate, making early detection difficult.”
CTS has been reported as the most common symptom of TTR-CA and is strongly associated with ATTRwt. However, while CTS is a frequent encounter in orthopedic practice, many orthopedic surgeons are unaware of its association.
The new study aimed to determine if an early diagnosis of CTS can contribute to an early diagnosis of ATTRwt, as well as how frequently orthopedic surgeons consult with cardiologists regarding these cases. The data set consisted of 42 cases of diagnosed ATTRwt at the Juntendo University Faculty of Medicine in Tokyo, Japan, from August 2019 to December 2024. There were 34 males and 8 females with a mean age of 77.7 years. Cases excluded from the study were those where genetic testing was not performed, those diagnosed with ATTRv, those who died or dropped out before a definitive diagnosis, and those with incomplete data.
Out of the 42 cases diagnosed with ATTRwt, 26 (61.9%) had a history of CTS and 16 (38.1%) did not. Of the 26 cases that were diagnosed with ATTRwt and had a history of CTS, 15 (57.7%) had bilateral CTS, and the other 11 (42.3%) had unilateral CTS. Furthermore, out of the 26 cases, 24 (92.3%) were first diagnosed with CTS before being definitively diagnosed with ATTRwt, unlike the remaining 2 (7.7%), who developed CTS after being diagnosed with ATTRwt. The average time between the CTS and ATTRwt diagnoses for those who had a history of CTS before being diagnosed with ATTRwt was 6.7 years (range, 0-29 years). Overall, amongst the 26 participants that had a history of CTS, 4 died within an average of 17.5 months (range, 2-39 months) after the definitive ATTRwt diagnosis.
Additionally, out of all 42 cases of diagnosed ATTRwt, there were only 4 cases in which the cardiologist consulted an orthopedic surgeon about the differential diagnosis of CTS, but none vice versa. The study was limited in size, as there were only 42 cases assessed that met the criteria. Further limitations included that the presence of CTS was evaluated based on "history of CTS” in patient records, but because symptoms can vary in severity and latency, it is possible there were false negative diagnoses of CTS amongst participants. Additionally, both surgical and conservative treatments for CTS were included in the case study, which also revealed that the risk of developing amyloidosis was higher amongst participants who underwent CTS surgery.
Previous studies have reported that 40% to 50% of patients diagnosed with ATTRwt also had a history of CTS.1 Another meta-analysis of 15 studies, which included 1416 patients, evaluated the relationship between CTS and CA. The results showed that 38% of patients with CA also had a history of CTS, but only 13% of patients with CTS developed CA, and the approximate time of CA development from the initial diagnosis of CTS was 7.02 years.2
“In light of the above, future research needs to focus on larger-scale studies, meta-analyses, and prospective studies to examine the relationship between CTS and ATTRwt in more detail,” the study authors wrote.
References
1. Goto K, Ikeguchi R, Noguchi T, Naito K, Ishijima M, Matsuda S. The relationship between carpal tunnel syndrome and wild-type ATTR amyloidosis. The Journal of Hand Surgery (Asian-Pacific Volume). Published online July 14, 2025. doi:10.1142/s2424835525500559
2. Elghouneimy M A, Bushara N, Abdelwahab O A, et al. (December 12, 2024) Carpal tunnel syndrome as a potential indicator of cardiac amyloidosis: a systematic review and meta-analysis. Cureus. 16(12):e75582. doi:10.7759/cureus75582
Hormone Therapy Use Differentially Associated With Breast Cancer Subtypes
July 16th 2025Estrogen-progestin hormone therapy used to manage menopausal symptoms and other women’s health conditions is associated with a higher risk of developing luminal-like breast cancer subtypes and other subtypes.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Intermountain Healthcare and Story Health Partner to Optimize Rural Heart Failure Care
February 7th 2023On this episode of Managed Care Cast, we speak with Tom Stanis, CEO and cofounder of Story Health, and Phillip Wood, Intermountain Ventures program director, on how their partnership came about, how it is going so far, and the future of their collaboration.
Listen
Value-Based Care Is Key to Bringing Cardiology Breakthroughs to Those Who Will Benefit Most
March 13th 2025On December 10, 2024, cardiologists, researchers, and value-based care experts gathered in Dallas, Texas, to discuss best practices for implementing advances in cardiology care with a value-based mindset, spanning the care continuum from prevention to treatment.
Read More
Closing the Gaps in Cardiac Care With Technology, Collaboration
March 12th 2025Cardiologists, primary care physicians, and value-based care leaders convened in Phoenix, Arizona, on November 12, 2024, to share case studies and insights on how to align cardiology with the principles of value-based care, including through the application of digital tools.
Read More